IM Cannabis Corp IMCC, a Canadian medical cannabis provider, released its Q3 2023 financial figures on Monday, disclosing revenue of CA$12.4 million ($8.99 million) down by 13% compared to the third quarter of 2022.
Q3 2023 Financial Highlights
- Revenue saw a 13% decrease, totaling CA$12.4 million.
- Net Loss from Continuing Operations was CA$2.1 million, compared to CA$4.5 million in the third quarter of 2022.
- Adjusted EBITDA loss in the third quarter of 2023 was CA$1.3 million, a decrease of 65% compared to the third quarter of 2022.
- Gross profit was CA$2.6 million, compared to CA$2 million in the third quarter of 2022, an increase of 30%.
- Operating loss in the third quarter of 2023 was CA$2.3 million, compared to CA$5.5 million in the third quarter of 2022, a decrease of 58%.
Despite a challenging economic backdrop marked by currency fluctuations, the IM Cannabis (IMC) showcased resilience with a 10% gross margin increase and 30% rise in gross profit.
Management Commentary
“As in the previous quarters, in Q3 2023, we continued towards our goal of sustainable profitability,” said Oren Shuster, IMC’s CEO, noting the company’s efforts to adjust its portfolio and focus on high-end products in the Israeli market.
Itay Vago, CFO, underscored the impact of currency volatility but emphasized ongoing operational cost reductions.
Operational Developments and Market Shifts
This period witnessed the launch of high THC strains and cost-saving measures like outsourcing delivery services, projected to save CA$300,000 annually.
However, geopolitical tensions with the recent Israel-Hamas conflict may cast future uncertainties on the market.
IMCC Price Action
IMCC's shares were trading 1.03% higher at $0.44 per share at the time of this writing Tuesday afternoon.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.